PMID- 34894842
OWN - NLM
STAT- MEDLINE
DCOM- 20220502
LR  - 20220904
IS  - 1461-7285 (Electronic)
IS  - 0269-8811 (Linking)
VI  - 36
IP  - 3
DP  - 2022 Mar
TI  - Debunking the myth of 'Blue Mondays': No evidence of affect drop after taking 
      clinical MDMA.
PG  - 360-367
LID - 10.1177/02698811211055809 [doi]
AB  - BACKGROUND: Incorporating 3,4-methylenedioxymethamphetamine (MDMA) as an adjunct 
      to psychotherapy has shown promise in recent years for treating various mental 
      health conditions, particularly those involving trauma. However, concerns about 
      declines in mood and cognition during the days following dosing, also known as 
      'Blue Mondays', have been raised as limitations to its clinical use. Although 
      these changes have been well-documented among recreational users, there are 
      critical confounds to these reports that limit generalizability to clinically 
      administered MDMA. AIMS: Here, we aimed to evaluate the evidence basis for the 
      negative side effects associated with MDMA as well as inform our understanding of 
      the drug's post-acute effects in a clinical context with an open-label study. 
      METHODS: The current open-label study examined MDMA therapy for alcohol use 
      disorder (AUD; N = 14) and measured mood, sleep quality, illicit MDMA consumption 
      and anecdotal reports after the acute drug effects had worn off. RESULTS: 
      Participants maintained a positive mood during the week following drug 
      administration in a clinical context. Relative to baseline, self-reported sleep 
      quality improved at the 3- and 6-month follow-ups. Finally, no participants 
      reported using or desiring to use illicit MDMA, and the anecdotal reports 
      indicated that they perceived the treatment favourably. CONCLUSION: The results 
      support the overall safety and tolerability of clinically administered MDMA and, 
      importantly, suggest that the 'come downs' previously associated with the 
      substance may be explained by confounds in research relating to the illicit 
      sourcing of the drug and specific environmental setting for recreational 
      consumption.
FAU - Sessa, Ben
AU  - Sessa B
AUID- ORCID: 0000-0002-1212-6060
AD  - Centre for Neuropsychopharmacology, Imperial College London, London, UK.
FAU - Aday, Jacob S
AU  - Aday JS
AUID- ORCID: 0000-0003-0578-8530
AD  - Department of Psychology, Central Michigan University, Mount Pleasant, MI, USA.
AD  - Department of Psychiatry and Behavioral Sciences, University of California, San 
      Francisco, San Francisco, CA, USA.
AD  - DrugScience, London, UK.
FAU - O'Brien, Steve
AU  - O'Brien S
AD  - Centre for Neuropsychopharmacology, Imperial College London, London, UK.
FAU - Curran, H Valerie
AU  - Curran HV
AD  - Research Department of Clinical, Educational & Health Psychology, University 
      College London, London, UK.
AD  - National Institute for Health Research University College London Hospitals 
      Biomedical Research Centre, London, UK.
FAU - Measham, Fiona
AU  - Measham F
AD  - Department of Sociology, Social Policy and Criminology, University of Liverpool, 
      Liverpool, UK.
FAU - Higbed, Laurie
AU  - Higbed L
AD  - Centre for Neuropsychopharmacology, Imperial College London, London, UK.
FAU - Nutt, David J
AU  - Nutt DJ
AD  - Centre for Neuropsychopharmacology, Imperial College London, London, UK.
AD  - DrugScience, London, UK.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211213
PL  - United States
TA  - J Psychopharmacol
JT  - Journal of psychopharmacology (Oxford, England)
JID - 8907828
RN  - 0 (Hallucinogens)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
CIN - J Psychopharmacol. 2022 Aug;36(8):1001-1004. PMID: 35924889
CIN - J Psychopharmacol. 2022 Aug;36(8):1001-1004. PMID: 35924890
MH  - Affect
MH  - Alcohol Drinking/psychology
MH  - *Alcoholism/drug therapy
MH  - Cognition
MH  - *Hallucinogens/adverse effects
MH  - Humans
MH  - *N-Methyl-3,4-methylenedioxyamphetamine/adverse effects
OTO - NOTNLM
OT  - *Blue Mondays
OT  - *MDMA
OT  - *alcohol use disorder
OT  - *come downs
OT  - *ecstasy
OT  - *psychotherapy
EDAT- 2021/12/14 06:00
MHDA- 2022/05/03 06:00
CRDT- 2021/12/13 11:20
PHST- 2021/12/14 06:00 [pubmed]
PHST- 2022/05/03 06:00 [medline]
PHST- 2021/12/13 11:20 [entrez]
AID - 10.1177/02698811211055809 [doi]
PST - ppublish
SO  - J Psychopharmacol. 2022 Mar;36(3):360-367. doi: 10.1177/02698811211055809. Epub 
      2021 Dec 13.